Background {#Sec1}
==========

Antibiotic use is increasing worldwide and has been implicated in the dramatic rise of antimicrobial resistance, which in turn threatens to reverse historical reductions in mortality for infectious diseases \[[@CR1]\]. Few treatment options remain, for example, for Enterobacteriaceae, which are increasingly resistant to beta-lactam antibiotics due to production of extended spectrum beta-lactamase (ESBL), AmpC, and carbapenemases. Infections with drug-resistant Enterobacteriaceae, such as those producing ESBL, have been associated with increased mortality \[[@CR2]\].

The gut serves as a reservoir for drug-resistant Enterobacteriaceae \[[@CR3]\]. Antibiotic administration increases drug-resistant Enterobacteriaceae colonization through selection pressure and disruption of protective normal microbiota \[[@CR3], [@CR4]\]. Animal models show a disruption to the gut microbiome within 12 h and emergence of drug resistance genes within 3 days of antibiotic administration \[[@CR5], [@CR6]\]. Patients colonized with ESBL-producing Enterobacteriaceae are at greater risk for clinical infections with ESBL-producing Enterobacteriaceae than those who are not colonized \[[@CR7]\].

In resource-limited settings, colonization with drug-resistant Enterobacteriaceae is common in adults, and, in community-based populations, associated with antibiotic use \[[@CR8]--[@CR10]\]. However, risk factors for inpatient acquisition of colonization with drug-resistant Enterobacteriaceae have not been clearly defined. As the world's largest consumer of antibiotics \[[@CR11]\], India has among the highest burdens of antimicrobial resistance worldwide \[[@CR12]--[@CR14]\]. Travelers from high income countries to India return home colonized with ESBL-producing Enterobacteriaceae more frequently than travelers to other countries, suggesting that India has a heavier burden of drug-resistant Enterobacteriaceae colonization compared to other low and middle income countries \[[@CR15], [@CR16]\].

In this study, we sought to assess the clinical factors associated with ceftriaxone- and carbapenem-resistant Enterobacteriaceae colonization among adults and children admitted to a tertiary care hospital in Pune, India. Given prior work suggesting an association with antibiotic use, we enrolled patients with acute febrile illness, a group likely to be treated with antibiotics \[[@CR17]\].

Methods {#Sec2}
=======

Setting and participants {#Sec3}
------------------------

Between August 2013 and December 2015, we prospectively enrolled adults and children admitted to medicine and pediatric wards with acute febrile illness at Byramjee Jeejeebhoy Government Medical College -- Sassoon General Hospital, Pune, India, to assess antimicrobial resistance as previously reported \[[@CR18]\]. Sassoon General Hospital is a 1300 bed public teaching hospital in Pune, a densely populated city in Maharashtra, India with a metropolitan population exceeding 5 million. We included patients greater than 6 months of age, with self-reported or measured fever ≥38.0 °C of more than 24 h duration who were screened within 1 day of admission. We excluded inpatient transfers from other hospitals, minor-age orphans, and medical-legal cases. A dedicated study physician and social worker obtained a standardized clinical and social history at the time of enrollment. After discharge, or on day 7 of enrollment, the study physician reviewed medication administration records and laboratory investigation results from the medical record.

Sample collection and processing {#Sec4}
--------------------------------

Between September 2014 and November 2015, a dedicated study nurse collected perirectal swabs on admission and on day 3 or 4 of hospitalization. Swabs were stored at − 80 °C pending processing \[[@CR19], [@CR20]\]. Swabs were placed into peptone broth impregnated with ceftriaxone and vancomycin. After incubating for 24 h, samples were plated onto MacConkey and sheep blood agar and incubated at 37 °C for 18 h. Isolates observed were loaded onto a Phoenix® Automated Microbiology System (Becton Dickinson) according to the manufacturer's instructions. The Phoenix® Automated Microbiology System performs species identification and drug susceptibility testing using a cartridge-based, broth microdilution system with a redox growth indicator \[[@CR21]\].

Definitions {#Sec5}
-----------

According to local hospital practice, patients \< 12 years of age are considered children and admitted to the pediatric ward, and those ≥12 years of age, adolescents and adults are admitted to the medicine ward. Resistance to individual antibiotics was determined using Clinical Laboratory Standards Institute (CLSI) guidelines (2014--2015) reported by the Phoenix® system \[[@CR21]\]. Gram-negative isolates that grew in the presence of ceftriaxone impregnated broth were considered to be ceftriaxone-resistant, with the exception of Pseudomonas isolates. ESBL- producing organisms were identified using the Phoenix® system, which employs rules to adjudicate the presence or absence of ESBL based on susceptibility to five cephalosporins alone or in combination with the beta-lactamase inhibitor, clavulanic acid \[[@CR21], [@CR22]\]. Enterobacteriaceae resistant to any carbapenem were considered to be carbapenem-resistant Enterobacteriaceae (CPRE) according to United States Centers for Disease Control and Prevention guidelines \[[@CR23]\]. As defined elsewhere, drug-resistant Enterobacteriaceae colonization was defined as hospital-acquired if samples were negative at enrollment and positive at \> 48 h of study \[[@CR24], [@CR25]\].

Analysis {#Sec6}
--------

Categorical variables were assessed for individual association with initial colonization, transition to colonization with drug-resistant Enterobacteriaceae isolates, and mortality using Fisher's exact test. The Wilcoxon rank sum test was used to assess length of hospital stay. Age was analyzed as a categorical variable stratified into five groups. A multivariable model was constructed assessing the association of predictor variables with acquisition of ceftriaxone-resistant Enterobacteriaceae (CTRE) colonization, adjusted for admission to the intensive care unit (ICU), sex, and age. Logistic regression was performed to assess predictor variables associated with all-cause mortality. Given the small sample size of CPRE colonization events, only bivariable analyses were performed. Statistical analyses were performed using R software \[[@CR26]\].

Results {#Sec7}
=======

Study population {#Sec8}
----------------

Between September 2014 and October 2015, 29,146 patients were admitted to adult and pediatric wards, 3589 had admission diagnoses suggestive of febrile illness, 1943 had subjective or documented fever, 1010 met all eligibility criteria and were enrolled in the parent study, 897 (89%) participants were enrolled in the substudy and had baseline perirectal swabs collected. Of the 897 study participants, 358 (40%) were children less than 12 years of age, 538 (60%) were male, 131 (15%) had been hospitalized within the past 3 months, and 214 (24%) reported using antibiotics in the month prior to admission (Table [1](#Tab1){ref-type="table"}).Table 1Demographics and clinical characteristics of patients with and without ceftriaxone-resistant Enterobacteriaceae colonization at enrollmentPatient characteristicColonization with ceftriaxone-resistant Enterobacteriaceae, n (%) or median (IQR)*p*-valueNot colonized, *n* = 810Colonized, *n* = 87Median age, years19 (4--35)23 (8--40)0.07Children (age \<  12 years)332 (41)26 (30)0.05Male487 (60)51 (59)0.82Diabetes34 (4)5 (6)0.42HIV85 (19)11 (20)0.86Alcoholism57 (7)1 (1)0.04Smoking67 (8)7 (8)1.00Income \< 5000 INR per month^a^281 (35)23 (26)0.15Works with animals^a^150 (19)20 (23)0.31Farmer or laborer^a^317 (39)32 (37)0.73General practitioner visit prior to hospitalization273 (36)37 (44)0.19Ayurvedic provider visit prior to hospitalization36 (5)8 (9)0.12Hospitalized within the past 3 months113 (14)18 (21)0.11Self-report of antibiotic use in the last month188 (23)26 (30)0.19Recent healthcare contact^b^456 (56)65 (75)\< 0.01Admission to ICU153 (19)13 (15)0.47Cough370 (46)32 (37)0.14Diarrhea154 (19)16 (18)1.00*IQR* interquartile range, *INR* Indian rupees, ICU intensive care unit^a^For children, this refers to the parents^b^Composite of visit to general practitioner or ayurvedic provider, hospitalization within the past 3 months, or self-reported antibiotic use in the last month

Drug-resistant Enterobacteriaceae colonization at admission {#Sec9}
-----------------------------------------------------------

Of 897 participants, 91 (10%) demonstrated growth of a Gram-negative rod (GNR) in ceftriaxone-impregnated media at admission, 87 (9.7%) demonstrated growth of an Enterobacteriaceae. Colonization with CTRE at enrollment was higher in participants who had recent contact with the healthcare system including recently hospitalization, outpatient visit prior to hospitalization, or self-reported antibiotic use in the last month (Table [1](#Tab1){ref-type="table"}). CPRE were found in 14 (1.6%) participants on admission -- 10 (1.9%) adults and four (1.1%) children. An additional four (0.4%) participants grew Enterobacteriaceae with intermediate carbapenem susceptibility (Additional file [1](#MOESM1){ref-type="media"}: Table S1).

Drug-resistant Enterobacteriaceae colonization at follow-up {#Sec10}
-----------------------------------------------------------

A total of 620 (69%) participants had follow-up swabs collected -- 530 on Day 3 and 90 on Day 4. Of 277 (31%) participants in whom a follow-up swab could not be collected, 212 had a hospital stay of 3 days or less (157 were discharged, 31 left against medical advice, 24 died), 30 refused collection of a second sample, and for 35 a second sample could not be obtained for other reasons (Fig. [1](#Fig1){ref-type="fig"}**)**. Participants without a follow-up swab were more likely to be adults (78% vs 52%, *p* \< 0.01) but were less likely to have HIV (12% vs 23%, *p* \< 0.01), to have been admitted to the hospital within the past 3 months (11% vs 16%, *p* \< 0.04), or to have been admitted to the intensive care unit (ICU) (13% vs 21%, *p* \< 0.01). There was no difference, however, in the proportion of participants receiving antibiotics (82% vs 85%, *p* = 0.23), including third generation cephalosporins (49% vs 48%, *p* = 0.89). Of 620 participants, 78 (13%) demonstrated growth of a GNR; 67 (11%) were identified as growing CTRE. CPRE were found in 21 (3.4%) participants including 8 (2.5%) adults and 13 (4.4%) children; 2 (0.3%) participants grew Enterobacteriaceae isolates with intermediate carbapenem susceptibility.Fig. 1Acquisition of ceftriaxone-resistant Enterobacteriaceae colonization. Abbreviations -- CTX: ceftriaxone; EB: Enterobacteriaceae

Of 561 (90%) participants without baseline resistant Enterobacteriaceae colonization, 49 (9%) were found to have colonization at follow-up (Table [2](#Tab2){ref-type="table"}). Extremes of age were associated with increased likelihood of CTRE colonization acquisition. Empiric therapy with a third generation cephalosporin was also associated with acquisition of CTRE colonization (71% received cephalosporin vs. 46% did not, p \< 0.01) (Table [2](#Tab2){ref-type="table"}). In multivariable analysis, adjusting for age, sex, ICU admission, and third generation cephalosporin initial antibiotic prescription, advanced age and third generation cephalosporin use remained significantly associated with acquisition of CTRE colonization, with cephalosporin use demonstrating nearly 3 times higher odds of acquisition (adjusted OR 2.9, 95% CI 1.5--5.8) (Table [2](#Tab2){ref-type="table"}).Table 2Factors associated with detection of ceftriaxone-resistant Enterobacteriaceae colonization among 561 patients without ceftriaxone-resistant Enterobacteriaceae colonization at enrollmentRisk Factor, n (%)Ceftriaxone-resistant Enterobacteriaceae colonization, n (%)Unadjusted OR (95% CI)*p*-valueAdjusted OR^a^ (95% CI)*p*-valueNo acquisition, *N* = 512Acquisition, *N* = 49Age in years  \< 5163 (32)21 (43)4.7 (1.3--29.9)0.044.4 (1.2--28.7)0.06 5--1188 (17)5 (10)2.1 (0.4--14.8)0.392.0 (0.4--14.6)0.41 12--2373 (14)2 (4)RefRefRefRef 24--59154 (30)15 (31)3.6 (1--22.9)0.13.8 (1--24.9)0.08  ≥ 6034 (7)6 (12)6.4 (1.4--45.5)0.037.0 (1.5--50.1)0.02 Male sex307 (60)33 (67)1.4 (0.7--2.8)0.361.5 (0.8--2.9)0.23 Income \< 5000 INR / month183 (36)23 (47)1.6 (0.0--8-3)0.12 Farmer or laborer203 (40)24 (49)1.5 (0.8--2.7)0.22 HIV^b^56 (22)6 (27)1.3 (0.4--3.7)0.6 ICU102 (20)17 (35)2.1 (1.1--4.1)0.031.6 (0.8--3.4)0.18Pre-hospital antibiotic use Within the past week99 (19)13 (27)1.5 (0.7--3.0)0.26 Within the past month121 (24)14 (29)1.3 (0.6--2.6)0.48Initial inpatient antibiotic Rx Any antibiotic432 (84)45 (92)2.1 (0.7--8.2)0.21 Multiple antibiotics240 (47)30 (61)1.8 (0.9--3.5)0.07 3rd-gen cephalosporin234 (46)35 (71)3.0 (1.5--6.1)\< .012.9 (1.5--5.8)\< 0.01 Fluoroquinolone19 (4)1 (2)0.5 (0.0--3.6)1 Macrolide96 (19)13 (27)1.6 (0.7--3.2)0.19 Aminoglycoside53 (10)8 (16)1.7 (0.6--3.9)0.23*OR* odds ratio, *IQR* interquartile range, *ICU* intensive care unit, *INR* Indian rupees, *Rx* prescription^a^Adjusted for age, sex, ICU admission, and third generation cephalosporin initial antibiotic prescription^b^HIV test results were available for 249 patients without ceftriaxone-resistant Enterobacteriaceae acquisition and 22 patients with ceftriaxone-resistant Enterobacteriaceae acquisition

There were 19 (3%) participants (13 adults and 6 children) who on admission were not colonized with CPRE, but were found to have CPRE colonization on follow-up. Children under age 5 were most likely to acquire CPRE colonization compared to other age categories (OR 4.1, 95% CI 1.3--18.4). Participants who acquired CPRE were more likely to be admitted to the ICU (OR 3.0, 95% CI 1.0--8.5) and more likely to have received empiric aminoglycosides (OR 4.2, 95% CI 1.2--4.3). There was notably an association between ICU admission and aminoglycoside use, *p* \< 0.001.

Among 59 (9%) participants found to have CTRE colonization at enrollment in whom follow-up samples were collected, colonization remained detectable in 22 (37%) participants (Fig. [1](#Fig1){ref-type="fig"}). CTRE Use of third-generation cephalosporins was not associated with loss of detection of CTRE colonization (*p* = 0.79). Among the 14 participants found to have CPRE colonization at enrollment, follow-up samples were collected on 12 participants, of which two (17%) continued to demonstrate CPRE colonization.

Perirectal isolate species and antimicrobial resistance patterns {#Sec11}
----------------------------------------------------------------

The 136 participants with CTRE identified in either enrollment or follow-up samples comprised 52 (14%) of the enrolled children and 84 (16%) of the enrolled adults. Five specimens grew two different CTRE species. Of the 101 ceftriaxone-resistant *Escherichia coli* isolates, 77 (76%) were identified as ESBL producers by Phoenix®, while 32 of 49 (65%) *Klebsiella* isolates were identified as ESBL producers (Table [3](#Tab3){ref-type="table"}). Though the Phoenix® system does not report the presence of AmpC as part of the resistance profile for identified organisms, cefoxitin resistance may suggest the presence of AmpC, particularly in the context of a ceftriaxone-resistant organism that is not flagged as an ESBL organism by Phoenix®. Both *E. coli* and *Klebsiella* species were mostly resistant to cefoxitin -- 66 and 63% respectively. None of the 11 *Enterobacter* isolates were considered to be ESBL isolates by Phoenix®, and all were resistant to cefoxitin, suggesting that AmpC was the likely mechanism of resistance for the *Enterobacter* isolates.Table 3Isolate species and resistance pattern among 179 Gram-negative perirectal isolatesSpeciesn (%)ESBL, n (%)Cefoxitin resistant, n (%)Carbapenem resistant, n (%)All isolates179 (100)----38 (21)*Pseudomonas* species14 (8)----2 (14)*Comamonas* species2 (1)----0*Moraxella* species1 (0.6)----0All Enterobacteriaceae162 (91)109 (67)110 (68)36 (22) *Escherichia coli*101 (78)77 (76)67 (66)16 (15) *Klebsiella pneumoniae*49 (27)32 (65)31 (63)16 (33) *Enterobacter* species11 (6)011 (100)3 (27) *Citrobacter farmeri*1 (0.6)01 (100)1 (100)*ESBL* extended spectrum beta-lactamase

Clinical outcomes {#Sec12}
-----------------

The median length of stay among the 897 participants was 4.0 days, interquartile range (IQR) (3--7); 4.0 days (IQR 2--6) for adults and 5.5 days (IQR 4--9) for children. Among participants who had follow-up samples collected, median length of stay was 6.0 days (IQR 4--9). There was no association with length of stay and Enterobacteriaceae colonization at follow-up, *p* = 0.35. There were 34 deaths (6%) among participants with collected follow-up samples. Participants who were colonized at follow-up were more likely to die. Among 71 participants who were colonized with CTRE at follow-up there were 8 (11%) deaths, whereas among 549 participants who were not colonized there were 26 (5%) deaths (*p* = 0.02) (Table [4](#Tab4){ref-type="table"}). In a multivariable model adjusted for age \<  12 years and admission to the ICU, CTRE colonization was no longer associated with mortality (AOR 2.4, 95% CI 0.9--6.0) (Table [4](#Tab4){ref-type="table"}). There were three (9%) deaths among participants who were colonized with CPRE at enrollment or follow-up.Table 4Factors associated with mortality among patients who completed follow-up (*N* = 580)^a^Clinical FactorSurvived, *N* = 546, n (%)Died, *N* = 34, n (%)Unadjusted OR (95% CI)*p*-valueAdjusted OR^b^ (95% CI)*p*-valueMale sex321 (59)23 (68)1.5 (0.7--3.4)0.37----Child \< 12 years267 (49)11 (32)0.5 (0.2--1.1)0.080.2 (0.1--0.4)\< 0.01Income \< 5000 INR / month197 (36)15 (44)1.4 (0.6--3)0.36----Diabetes18 (3)1 (3)0.9 (0--6)1----HIV56 (10)7 (21)2 (0.6--5.7)0.17----Diarrhea110 (20)9 (26)1.4 (0.6--3.3)0.38----Cough278 (51)13 (38)0.6 (0.3--1.3)0.16----ICU admission96 (18)19 (56)6.8 (3.1--15.6)\< .0114.7 (6.1--36.9)\< 0.01Admission ceftriaxone-resistant EB colonization52 (10)2 (6)0.6 (0.1--2.4)0.76----Follow-up ceftriaxone-resistant EB colonization53 (10)8 (24)2.9 (1.1--6.9)0.022.4 (0.9--6.0)0.06Acquisition of ceftriaxone-resistant EB colonization37 (7)6 (18)2.8 (0.9--7.7)0.04----*OR* odds ratio, *INR* Indian Rupees, *ICU* intensive care unit, *EB* Enterobacteriaceae^a^Mortality data was not available for 40 (6%) of patients who completed follow-up perirectal swab collection^b^Adjusted for child \< 12 years, ICU admission, and colonization with ceftriaxone-resistant EB at follow-up

Discussion {#Sec13}
==========

Our study has several key findings. First, we identified a 10% prevalence of community-acquired ceftriaxone-resistant GNR colonization and 1.6% colonization with CPRE among Indian adults and children admitted with acute febrile illness. Second, we observed that healthcare contact was associated with increased odds of admission CTRE colonization. Third, we found that participants without baseline CTRE colonization who received empiric third generation cephalosporins had almost three-fold higher odds of follow up detection of CTRE colonization, and were more likely to acquire CPRE colonization if admitted to the ICU.

The 10% rate of community-acquired CTRE colonization reported in this study is comparable to rates of 10--15% reported in studies that used rectal and perirectal swabs to detect colonization \[[@CR27], [@CR28]\], and to another study of children in India showing 13% of children to have ceftriaxone-resistant *E. coli* colonization \[[@CR29]\]. The rate was lower than the 23--69% ESBL-Enterobacteriaceae colonization rate reported among healthy adults from other resource limited Asian settings that determined colonization using higher inoculum stool samples \[[@CR8], [@CR9]\]. While obtaining a stool specimen from healthy volunteers at a time of convenience may be practical for community surveillance studies, in order to assess dynamic colonization during hospitalization, perirectal swab collection at specific time intervals is more practical than stool culture.

Admission CTRE colonization was no longer detected at follow-up for almost two-thirds of CTRE colonized participants, a higher than expected proportion. Although some studies have shown persistence of multidrug-resistant Enterobacteriaceae for months after acquisition, others have shown that with daily screening, more than half of patients demonstrate intermittent colonization \[[@CR25], [@CR30], [@CR31]\]. As we only performed one follow-up culture, it is possible that further follow-up cultures may have revealed persistence of colonization in additional participants. However, because third-generation cephalosporin use was not associated with loss of detectable ceftriaxone-resistant GNR colonization, limitations in the CTRE colonization detection modality were not impacted by third-generation cephalosporin use.

Use of empiric third generation cephalosporins was associated with detection of CTRE colonization among participants not found to be colonized at admission, even when adjusted for other factors. Empiric aminoglycosides use was associated with acquisition of carbapenem-resistant Enterobacteriaceae colonization, but was likely confounded by ICU admission. From this study, we cannot determine if follow-up detection of drug-resistant Enterobacteriaceae colonization among participants without baseline colonization was due to nosocomial transmission or overgrowth of minority drug-resistant colonies in the presence of selection pressure from administered antibiotics. Most nosocomial acquisition of drug-resistant Enterobacteriaceae in studies conducted in resource-rich settings is not attributed to transmission from other hospitalized patients \[[@CR32], [@CR33]\]. However, a study in a resource-limited setting showed genetic similarities among acquired isolates suggesting nosocomial cross-transmission \[[@CR34]\].

Previous work in a resource-rich ICU setting has shown an association between drug-resistant Enterobacteriaceae colonization and mortality \[[@CR35]\], but similar data from resource-limited settings describing clinical associations with colonization is limited. We found that participants with CTRE colonization at follow-up were more likely to die in an unadjusted analysis. After adjusting for ICU admission and age, the association no longer remained statistically significant. Any association of CTRE colonization and mortality does not necessarily signify causality, as there may be unmeasured risk factors common to both CTRE colonization acquisition and mortality.

Unfettered antibiotic use has been implicated as one of the key factors driving global increasing antimicrobial resistance \[[@CR1]\]. Studies in other settings have demonstrated that antibiotic administration and ICU admission are associated with development of antibiotic-resistant bacterial stool colonization during the course of a hospitalization, but used longer intervals between enrollment and follow-up \[[@CR28], [@CR36]\]. The finding that initial empiric antibiotic choice can also significantly impact this process is concerning, especially given how commonly third generation cephalosporins are used in India and elsewhere.

Antimicrobial use may be tempered by antimicrobial stewardship policies, which were not yet in place at the time of this study. Guidelines offer two general antimicrobial stewardship approaches: preauthorization of antibiotics and auditing of antibiotic prescriptions after treatment initiation \[[@CR37], [@CR38]\]. De-escalation of antibiotic therapy was associated in a meta-analysis with decreased mortality risk \[[@CR39]\]. However, it remains unclear how quickly antibiotics should be de-escalated. Rapid acquisition of detectable resistant Enterobacteriaceae colonization, as noted in our study, may result in a narrow window of opportunity for prevention of drug-resistant organism colonization. A recent study notably failed to show a reduction in the emergence of multidrug-resistant Gram-negative infections after de-escalation of anti-pseudomonal beta-lactams \[[@CR40]\]. Our study design required participants to remain hospitalized through Day 3 or Day 4, which excluded both those with early mortality, and those with mild illness who were quickly discharged. However, among patients who do remain hospitalized through the third or fourth day of admission, the contribution of empiric antibiotics to drug-resistant Enterobacteriaceae colonization poses an antimicrobial stewardship concern.

Conclusions {#Sec14}
===========

In conclusion, colonization with drug-resistant Enterobacteriaceae is common among patients admitted with fever in Pune, India. Our study highlights the need for improved antimicrobial stewardship and infection control measures, which the World Health Organization acknowledges in its Global Action Plan on Antimicrobial Resistance \[[@CR41]\]. Physicians and governing bodies in India have recognized the threat of antimicrobial resistance responding with newly introduced legislation which requires a prescription for the sale of many advanced antibiotics including third and fourth generation cephalosporins \[[@CR12], [@CR42]\]. Continued surveillance of drug-resistant Enterobacteriaceae colonization in India and other resource-limited settings is warranted.
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===============

 {#Sec15}

Additional file 1:**Table S1.** Demographics and clinical characteristics of patients with and without carbapenem-resistant Enterobacteriaceae colonization at enrollment. (PDF 43 kb)
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